Following g-Proventil’s approval and successful completion of g-Advair’s Phase-3 clinical study, we believe CIPLA is well poised to expand its inhaler portfolio in the US market. We raise our ...

The American Lung Association in New York is proud to welcome Cipla back as the lead sponsor of the 2025 LUNG FORCE Walk New York City. As this year’s Breathe Free Sponsor, Cipla continues its ...

Drug maker Cipla on Wednesday said it has received approval ... Afrezza is a rapid-acting insulin delivered through an inhaler compared to current insulins which are given as injections.

Cipla share will remain in focus on Thursday ... Afrezza is a rapid-acting insulin delivered through an inhaler as compared ...

Cipla's protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for injectable suspension 100 mg/vial.

"Formosa Pharma welcomes this partnership with Cipla, a well-renowned and respected global pharmaceutical brand. We appreciate their recognition and desire to add APP13007 to their rich portfolio ...

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug. The company has received the final approval from the US Food and ...